The clinical efficacy of this treatment strategy has also been preliminarily validated: palbociclib combined with dexamethasone has exhibited targeted effects in patients with relapsed or refractory B-ALL, such as reduced expression of CD34+ cells, p-RB, c-MYB, and BCL-2 [52]. The gene discussed is BCL2; the disease is precursor B-cell acute lymphoblastic leukemia.